Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...
There is no exact known number of GLP-1 patients who say their say their sense of taste has changed since starting the ...
MedPage Today on MSNOpinion
'Most Favored Nation' Pricing May Cut Drug Costs. It May Also Cut Off Rural America.
In November, the Trump administration resurrected a Most Favored Nation (MFN) reference pricing policy, which would tie drug ...
13hon MSN
Is Eli Lilly a Buy Before 2026?
Eli Lilly’s next-generation obesity treatment may prove highly effective for patients who have high BMI or suffer from ...
19hon MSN
Where Will Eli Lilly Be in 10 Years?
Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...
24/7 Wall St. on MSN
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Allstate, Chubb Ltd., Eli Lilly, KLA Corp., Lockheed Martin, MongoDB, Roku, and More
The futures are trading lower after what started as a bounce-back Monday turned into a reversal Monday, as the AI/Datacenter ...
Zacks Investment Research on MSN
Eli Lilly or Merck: Where should investors put their money?
Eli Lilly LLY and Merck MRK are both major global pharmaceutical companies with blockbuster drug portfolios and deep ...
The Brown County Community Foundation is pleased to announce the recipient of the 2026 Lilly Endowment Community Scholarship ...
A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...
U.S. lawsuits against Novo Nordisk and Eli Lilly alleging patients taking weight loss drugs lost some or all of their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results